-

Bayer Wins Third Consecutive Trial Victory

Company has now won 13 of last 19 cases where judgments were entered at trial

WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer won its third consecutive trial victory when a jury reached a defense verdict in its most recent trial – the Kline Roundup™ product liability trial – before Judge Ann Butchart in Philadelphia.

Separately, Plaintiffs voluntarily dismissed with prejudice the Meyer case which was at trial in the Superior Court of California for Sonoma County. These follow the defense verdict in Cody in Conway County, Arkansas, as well as a mistrial in Cloud in Delaware state court, both occurring late last week.

Bayer has now won three consecutive victories at trial, and 13 of the last 19 cases where judgments were entered at trial.

“Validating the Company’s strategy of taking cases to trial based on strong scientific and regulatory evidence, Bayer has now won three consecutive victories at trial and 13 of the last 19 cases where judgments were entered at trial,” the company said. “In these cases, the plaintiffs could not prove that Roundup™ was the cause of the injuries alleged in these cases, consistent with this science.”

The unanimous Kline verdict is the first to follow significant rulings in the Philadelphia litigation clarifying which scientific and regulatory conclusions could be admitted, a much-disputed issue in prior trials.

“While we have great sympathy for anyone who suffers a loss or injury, science proves that Roundup™ is not carcinogenic,” said the company. “We continue to stand behind the safety of Roundup™ and will confidently defend the safety of our products and our good faith actions in any future litigation.”

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Bayer


Release Versions

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Bayer

New FDA 510(k) Clearance Expands Bayer’s MEDRAD® MRXperion MR Injection System Support Across Diverse Range of MR Environments

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for expanded capabilities of its MEDRAD® MRXperion Magnetic Resonance (MR) Injection System, a power injector designed to support efficient workflow and consistent contrast delivery across a broad range of MR environments. This updated clearance expands MRXperion’s labeled field strength compatibility to support magnetic resonance imaging (MRI) scanners with magnetic...

Bayer Reports Results for the Investigational Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

BERLIN--(BUSINESS WIRE)--Bayer today announced results from the ongoing global Phase I first-in-human, dose-escalation PAnTHa study (NCT06217822) evaluating the safety, tolerability and preliminary efficacy of 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy (TAT) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). The dose for expansion was successfully identified, with ≥80% of patients achieving a PSA50 response at the expansion dose....

Bayer’s XOFIGO® (radium-223 dichloride) Plus Enzalutamide Demonstrates Significant Overall Survival Benefit in PEACE-3 Trial in Patients With Metastatic Castration-Resistant Prostate Cancer With Bone Metastases

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases...
Back to Newsroom